
    
      [Pharmacokinetic Assessments]: Plasma concentrations of IN-C005 and its metabolite will be
      measured

        1. Single Dosing Group (Korean Subjects)

             -  Primary endpoints: Cmax and AUClast of IN-C005

             -  Secondary endpoints: AUClast, Cmax, AUCinf, Tmax, t½, CL/F, and Vd/F of M1; AUCinf,
                Tmax, t½, CL/F, and Vd/F of IN-C005

        2. Multiple Dosing Group (Caucasian Subjects)

             -  Primary endpoints: Cmax, AUClast, Cmax,ss, and AUCτ,ss of IN-C005

             -  Secondary endpoints: For M1, AUClast, Cmax, Cmax,ss, AUCinf, AUCτ,ss, Tmax,
                Tmax,ss, t½, CL/F, and Vd/F; for IN-C005, AUCinf, Tmax, Tmax,ss, Cmin,ss, t½, CL/F,
                Vd/F, Cav,ss, CLss/F, Vss/F, PTF (peak to trough fluctuation), and R (accumulation
                ratio)

      [Pharmacodynamic Assessments]:

        1. Single Dosing Group (Korean Subjects)

             -  Intragastric pH

                  -  Percent (%) duration of pH ≥4 in 24 hrs

                  -  Mean pH

                  -  Median pH

                  -  Change in pH from baseline to post-dose (Δduration %, Δmean pH, Δmedian pH,
                     etc.)

             -  Serum gastrin level

                  -  AUEGlast

                  -  Gmax

                  -  Change in gastrin level from baseline to study treatment (1d, 8d, and
                     15d)(ΔAUEGlast, ΔGmax, etc.)

        2. Multiple Dosing Group (Caucasian Subjects)

             -  Intragastric pH

                  -  Percent (%) duration of pH ≥4 in 24 hrs

                  -  Mean pH

                  -  Median pH

                  -  Change in pH from baseline to post-single dose and post-multiple doses
                     (Δduration %, Δmean pH, Δmedian pH, etc.)

             -  Serum gastrin level

                  -  AUEGlast

                  -  Gmax

                  -  Change in gastrin level from baseline to 1d and 7d (ΔAUEGlast, ΔGmax, etc.)

      [Safety Assessments] <Single Dosing Group (Korean Subjects) and Multiple Dosing Group
      (Caucasian Subjects)>

        1. AEs will be monitored with observable/objective symptoms, etc.

        2. Physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory
           tests
    
  